United States
25 years of research, business development, strategic partnerships and venture investing experience to development of new medicines and emerging healthcare technologies. Track record of advancing and investing in innovative technologies at public and private companies. Well established extensive global network across academia, biotechnology, pharmaceutical, foundations and investors. Career contributions include FDA drug approvals and marketed products, company acquisitions and IPOs. Keywords: early stage startup investment, operations, innovation advancement, business development, strategic planning, alliance management, corporate development, portfolio management, ecosystem building, Board member, venture, drug discovery, therapeutics, diagnostics, healthcare, executive management
Advance early innovation towards product development by bringing academia, industry and government together for technical and business expertise and funding.
Strategic consulting -- Fractional Management, Business Development, Partnerships, Early Stage Ventures, Investments, Build and Scale Innovation Ecosystems Clients include pharmaceuticals, venture capital, accelerators, startups, foundations and academia
Seed and Series A investor in companies spun out of Harrington Discovery Institute and elsewhere developing novel therapeutics.
Novo Nordisk’s Bio Innovation Hub, an R&D unit designed to accelerate the development of therapeutics via co-creative partnerships with academia, biotechs, venture capital groups and Pioneering Medicines, Flagship’s drug development initiative
Boston based life sciences virtual accelerator and investor that provides Seed and Series A investments along with strategic guidance, leadership and operational support. Xontogeny and Perceptive Advisors created the Perceptive Xontogeny Venture (PXV) Fund to support financing of portfolio companies. Xontogeny/PXV Fund invest in opportunities across therapeutics, diagnostics, medical devices and emerging healthtech. Report to CEO.